Anifrolumab: the new frontier in the treatment of genetic interferonopathies.

IF 5.1 2区医学 Q1 RHEUMATOLOGY RMD Open Pub Date : 2024-09-23 DOI:10.1136/rmdopen-2024-004780

Marie-Louise Frémond, Clémence David, Christophe Richez

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Anifrolumab：治疗遗传性干扰素病的新领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

RMD Open RHEUMATOLOGY-

CiteScore

7.30

自引率

6.50%

发文量

205

审稿时长

14 weeks

期刊介绍： RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

期刊最新文献

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries. Association between musculoskeletal sonographic features and response to treatment in patients with psoriatic arthritis. Value of the central sensitisation inventory in patients with axial spondyloarthritis. Baseline and 2-year differences in spinal symptoms and spinal and hip mobility in early axial spondyloarthritis and non-axial spondyloarthritis chronic back pain patients. Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins.